RANI Share Price Performance
US$0.92
0.39 (73.11%)
87.8% undervalued intrinsic discount
US$7.50
Fair Value
Price US$0.92
AnalystConsensusTarget US$7.50
AnalystHighTarget US$11.00
AnalystLowTarget US$5.00
Fair ValueUS$7.50
Share Pricen/a
Rani Therapeutics Holdings, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 26 Fair Values set on narratives written by author
RANI Community Narratives
AN
Fair Value
·Fair Value US$7.5 87.8% undervalued intrinsic discount
RANI: Future Pharma Partnership Will Unlock Major Deal Value Uplift
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
Fair Value
·Fair Value US$11 91.7% undervalued intrinsic discount
Needle-Free Oral Biologics Will Serve Aging Global Demand
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value
·Fair Value US$5 81.7% undervalued intrinsic discount
Early Clinical Uncertainty And Cash Runway Risk Will Shape Platform Potential Later
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
RANI: Future Pharma Partnership Will Unlock Major Deal Value Uplift
Rani Therapeutics is betting that its pill-like delivery tech can turn today’s injection-only biologic drugs into something patients can take by mouth, starting with a partnered obesity program. The upside comes with a catch: the company is burning cash and may need fresh funding before its lead program proves itself.Read more
AN
US$7.5
87.8% undervalued intrinsic discount
Fair Value
Profit Margin
19.68%
Future PE
431.74x
Price in 2029
US$5.12
Needle-Free Oral Biologics Will Serve Aging Global Demand
Rani Therapeutics is trying to turn popular injection-based medicines into easy-to-take pills, which could make it far more appealing for patients and doctors if the early human results hold up. The catch is it has limited cash and is betting heavily on one core technology, so delays, setbacks, or tougher competition could quickly change the story.Read more
AN
US$11
91.7% undervalued intrinsic discount
Fair Value
Profit Margin
19.69%
Future PE
225.65x
Price in 2029
US$7.51
Early Clinical Uncertainty And Cash Runway Risk Will Shape Platform Potential Later
Catalysts About Rani Therapeutics Holdings Rani Therapeutics Holdings is a clinical stage biotherapeutics company focused on enabling oral delivery of biologic drugs through its RaniPill capsule platform. What are the underlying business or industry changes driving this perspective?Read more
AN
US$5
81.7% undervalued intrinsic discount
Fair Value
Profit Margin
19.89%
Future PE
181.36x
Price in 2029
US$3.41
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
RANI: Cash Raise And Nasdaq Compliance Efforts Will Drive Future Upside
Fair Value: US$7.5 87.8% undervalued intrinsic discount
13 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
RANI: Follow-On Offering Will Support Obesity Capsule Trial Progress
Fair Value: US$11 91.7% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Early Clinical Uncertainty And Cash Runway Risk Will Shape Platform Potential Later
Fair Value: US$5 81.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Rani Therapeutics Holdings, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.26
- 100.00%
- -618.02%
- 0%
About RANI
- Founded
- 2012
- Employees
- 70
- CEO
- WebsiteView website
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai’s Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
